Results 61 to 70 of about 6,831 (145)

Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease. [PDF]

open access: yesFront Pharmacol, 2023
Murray SJ   +8 more
europepmc   +1 more source

A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes. [PDF]

open access: yesNeurotherapeutics, 2022
Swier VJ   +11 more
europepmc   +1 more source

Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease. [PDF]

open access: yesFront Genet, 2023
Mitchell NL   +12 more
europepmc   +1 more source

Lysosomal alterations and decreased electrophysiological activity in CLN3 disease patient-derived cortical neurons

open access: yesDisease Models & Mechanisms, 2022
Sueanne Chear   +12 more
doaj   +1 more source

Assessment of Safety and Biodistribution of AAVrh.10hCLN2 Following Intracisternal Administration in Nonhuman Primates for the Treatment of CLN2 Batten Disease. [PDF]

open access: yesHum Gene Ther, 2023
De BP   +14 more
europepmc   +1 more source

The Batten disease protein CLN8 is a stereospecific acyltransferase in bis(monoacylglycero)phosphate biosynthesis. [PDF]

open access: yesNat Cell Biol
Sheokand PK   +23 more
europepmc   +1 more source

Batten disease protein CLN8 enables a non-canonical phospholipid synthesis pathway. [PDF]

open access: yesNat Cell Biol
Breithofer J   +17 more
europepmc   +1 more source

TPC2 rescues lysosomal storage in mucolipidosis type IV, Niemann-Pick type C1, and Batten disease. [PDF]

open access: yesEMBO Mol Med, 2022
Scotto Rosato A   +29 more
europepmc   +1 more source

Special edition: The NCLs/Batten disease [PDF]

open access: yesBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2020
Rahim, AA, Russell, C, Mole, SE
openaire   +3 more sources

Home - About - Disclaimer - Privacy